H3K27M突变型弥漫性中线胶质瘤应进一步分子分层:669例患者整合分析
该研究整合已发表研究中669例H3K27M突变型弥漫性中线胶质瘤(H3-DMG)的个体患者数据,采用Kaplan-Meier分析和Cox回归评估额外基因改变对总生存的影响,发现TP53突变提示生存缩短,ACVR1、FGFR1突变和ATRX缺失与总生存改善相关,作者建议对此类肿瘤进一步分子分层。
要点
- TP53突变是H3-DMG中最常见的第二基因改变,与总生存缩短相关(HR 1.446;95%CI 1.143-1.829)。
- ACVR1突变(HR 0.712;95%CI 0.518-0.976)和FGFR1突变(HR 0.408;95%CI 0.208-0.799)与总生存延长相关。
- ATRX缺失亦与更好的总生存相关(HR 0.620;95%CI 0.386-0.996)。
核心结论
- 研究勾勒了H3-DMG中额外基因改变的预后重要性,并建议对此类肿瘤进一步分子分层,以助于神经肿瘤医生进行适当的风险分层。
研究设计与样本
- 整合已发表研究中个体患者数据的生存分析,检索PubMed和Web of Science,纳入有随访数据和H3-DMG额外分子检测数据的30项研究、共669例H3-DMG患者。
主要发现
- TP53突变是这些肿瘤中最常见的第二基因改变。
- 单因素Cox回归中,TP53突变提示生存缩短(HR 1.446;95%CI 1.143-1.829)。
- ACVR1突变(HR 0.712;95%CI 0.518-0.976)和FGFR1突变(HR 0.408;95%CI 0.208-0.799)与总生存延长相关。
- ATRX缺失亦与更好的总生存相关(HR 0.620;95%CI 0.386-0.996)。
- 校正年龄、性别和肿瘤位置后,TP53突变的存在、ACVR1或FGFR1突变的缺失仍为显著的 poor 预后因素。
关键数值与推荐
- 单因素Cox回归:TP53突变HR 1.446(95%CI 1.143-1.829);ACVR1突变HR 0.712(95%CI 0.518-0.976);FGFR1突变HR 0.408(95%CI 0.208-0.799);ATRX缺失HR 0.620(95%CI 0.386-0.996)。
- 校正年龄、性别和肿瘤位置后,TP53突变的存在、ACVR1或FGFR1突变的缺失仍为显著的 poor 预后因素。
临床怎么用
- 作者建议对这些肿瘤进一步分子分层,可能有助于神经肿瘤医生进行适当的风险分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: H3K27M-mutated diffuse midline gliomas (H3-DMGs) are aggressive tumors with a fatal outcome. This study integrating individual patient data (IPD) from published studies aimed to investigate the prognostic impact of different genetic alterations on survival of these patients. METHODS: We accessed PubMed and Web of Science to search for relevant articles. Studies were included if they have available data of follow-up and additional molecular investigation of H3-DMGs. For survival analysis, Kaplan-Meier analysis and Cox regression models were utilized, and corresponding hazard ratios (HR) and 95% confidence intervals (CI) were computed to analyze the impact of genetic events on overall survival (OS). RESULT: We included 30 studies with 669 H3-DMGs. TP53 mutations were the most common second alteration among these neoplasms. In univariate Cox regression model, TP53 mutation was an indicator of shortened survival (HR 1.446; 95% CI 1.143-1.829) whereas ACVR1 (HR 0.712; 95% CI 0.518-0.976) and FGFR1 mutations (HR 0.408; 95% CI 0.208-0.799) conferred prolonged survival. In addition, ATRX loss was also associated with a better OS (HR 0.620; 95% CI 0.386-0.996). Adjusted for age, gender, and tumor location, the presence of TP53 mutations, the absence of ACVR1 or FGFR1 mutations remained significantly poor prognostic factors. CONCLUSIONS: We outlined the prognostic importance of additional genetic alterations in H3-DMGs and recommended that these neoplasms should be further molecularly segregated. This may aid neuro-oncologists in appropriate risk stratification.
引用
- Vuong HG, Le HT, Ngo TNM, et al. H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients. J Neurooncol. 2021. PMID: 34796414. doi:10.1007/s11060-021-03890-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。